Video

Universal Screening for BRCA1 and BRCA2 Mutations

For High-Definition, Click

It has been suggested that all women should be screened for the BRCA1 and BRCA2 mutations in the course of routine medical care, notes Maurie Markman, MD. Ovarian cancer is rare, and routine screening for the general population is not warranted at this time, comments Michael J. Birrer, MD. If the general population were to be screened, appropriate follow-up and genetic counseling would need to be offered to all women who test positive, adds Warner K. Huh, MD.

Robert A. Burger, MD, remarks that factors such as family history and ethnicity should be considered when selecting patients for screening. Universal screening may be warranted in segments of the population with a high prevalence of disease, for example, women of Ashkenazi Jewish descent.

Related Videos
Cedric Pobel, MD
Kathleen N. Moore, MD, MS
Jennifer Scalici, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.